{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Ontuxizumab",
  "nciThesaurus": {
    "casRegistry": "946415-62-9",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized IgG1 monoclonal antibody directed against human endosialin/TEM1 (tumor endothelial marker;CD248) with potential anti-angiogenic and antineoplastic activities. Ontuxizumab binds to and inhibits the activity of cell surface protein endosialin/TEM1, which may result in the inhibition of angiogenesis, tumor cell proliferation and metastasis. Endosialin/TEM1 plays a key role in angiogenesis and may be overexpressed on tumor stromal cells and endothelial cells.",
    "fdaUniiCode": "0M2XT000YC",
    "identifier": "C82406",
    "preferredName": "Ontuxizumab",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129822",
      "C1742",
      "C20401"
    ],
    "synonyms": [
      "Immunoglobulin G1, Anti-(Human Protein TEM1 (Tumor Endothelial Marker 1)) (Human-Mouse Monoclonal MORAb-004 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-004 kappa-chain, Dimer",
      "MORAb-004",
      "ONTUXIZUMAB",
      "Ontuxizumab"
    ]
  }
}